Agenda
Virtual Workshop A
March 2, 2027 • 9:00 am–12:00 pm ET
Keeping Canada in the Clinical Development Pipeline: Strengthening Evidence Generation and Market Access
Virtual Workshop B
March 2, 2027 • 1:00–4:00 pm ET
From Evidence to Reimbursement—Stress-Testing a Canadian HTA Submission
Day 1 — Main Conference
March 10, 2027
Registration & Continental Breakfast
Co-Chairs’ Opening Remarks
MFN Drug Pricing: Global Implications for Canada’s Pharmaceutical Competitiveness and Patient Access
U.S. most-favoured-nation (MFN) drug pricing policies could reshape global pricing, medicine launch strategies and pharmaceutical investment, with implications for Canada’s competitiveness, medicine availability and patient access.
This session will examine the impact of MFN policies on Canada’s pharmaceutical landscape, how broadly U.S. patients can access needed medicines through public and private coverage, and the implications for innovative therapies, including orphan and rare disease drugs and cell and gene therapies.
- Assessing MFN’s impact on Canadian drug launches and pricing strategies
- Examining how U.S. patients access needed medicines and where coverage gaps remain
- Exploring implications for rare disease drugs and advanced therapies
- Identifying strategies to address international pricing pressures while protecting Canada’s pharmaceutical competitiveness and patient access
Morning Break & Networking
The Pharmaceutical and Life Sciences Sector Task Force has put forward recommendations to strengthen Canada’s life sciences sector and improve its pharmaceutical environment. With some initiatives already underway, attention is turning to the federal government’s consideration of the recommendations and the next steps needed to advance them.
This session will examine the status of the Task Force recommendations, the federal government’s progress in considering them, and opportunities for collaboration with industry and other stakeholders to advance proposed initiatives.
- Assessing the implications of proposed policy and regulatory changes
- Identifying priorities for advancing initiatives already underway
- Clarifying stakeholder roles and responsibilities in implementation
- Establishing measures to monitor progress and evaluate outcomes
Canada’s evolving reimbursement processes aim to improve predictability and accelerate patient access, but faster HTA reviews alone cannot guarantee public coverage.
Using the pCPA Temporary Access Process experiences of Enhertu and Zepzelca, this case study will examine how early access pathways work in practice, the factors shaping negotiation outcomes, and the challenges of transitioning from temporary access to longer-term public coverage.
- Examining practical lessons from the two Temporary Access Process experience
- Identifying factors influencing payer negotiations and potential barriers to public coverage
- Assessing implications for submission planning and reimbursement timelines in light of CDA-AMC’s 180-day review target
Networking Lunch
Quebec’s pharmaceutical policy environment presents distinct considerations for manufacturers, payers and other stakeholders navigating market access. Changes under Bill 67, including expanded pharmacist responsibilities, may influence prescribing, dispensing and how patients obtain and manage treatment.
This session will examine the implications for pharmacy engagement, biosimilar competition and manufacturer market-access strategies.
- Assessing how Bill 67’s expanded pharmacist responsibilities may affect prescribing, dispensing and patient access
- Evaluating the factors shaping biosimilar uptake, market competition and manufacturer engagement in Québec
- Navigating Québec-specific drug assessment, reimbursement and listing requirements to inform market-access planning
Public and Private Drug Coverage in Canada: Rethinking Affordability, Access and Payer Responsibilities
Federal pharmacare initiatives and provincial policy changes are reshaping Canada’s drug coverage landscape, while private insurers and employers continue to play an important role in access to innovative and specialty medicines. Developments such as Alberta’s Bill 11 are raising important questions about the respective responsibilities of public and private payers, the design of drug benefits and coordination between coverage programs.
This session will examine how evolving public and private coverage models affect payer responsibilities, benefit design and patient access, and what these changes mean for governments, insurers, employers and the pharmaceutical industry.
- Assessing how shifting payer responsibilities affect pharmaceutical market access
- Identifying approaches to address gaps in coverage for innovative and specialty medicines
- Exploring strategies to balance benefit affordability, coverage adequacy and long-term plan sustainability
Afternoon Refreshment & Networking
Over the next decade, hundreds of medicines are expected to face patent expiry, creating significant opportunities for generic and biosimilar competition and potential savings for Canada’s public and private drug plans. However, realizing these savings depends on more than patent expiry alone. Market entry, pricing policies, regulatory requirements and uptake all influence the extent to which increased competition translates into lower drug costs.
Drawing on recent analysis of upcoming patent expiries and their potential impact on Canadian drug spending, this session will examine how governments, payers and industry can address barriers to competition, capture potential savings and support a competitive and sustainable medicines market.
- Evaluating the policy and market conditions needed to accelerate generic and biosimilar entry
- Prioritizing opportunities to realize savings from upcoming patent expiries across therapeutic areas
- Developing approaches to foster a competitive medicines market while sustaining incentives for innovation
Canada faces continuing challenges in pharmaceutical competitiveness, reimbursement predictability and equitable access. Bringing together perspectives from manufacturers, public and private payers, policy leaders and patient representatives, this interactive roundtable will move beyond identifying system challenges to prioritize practical reforms.
- Prioritizing two or three actionable reforms to improve market access and reimbursement in Canada
- Integrating patient, payer, industry and government perspectives to strengthen policy development and implementation
- Identifying opportunities for cross-sector collaboration and defining practical next steps to advance reform
Closing Remarks & Conference Adjourns to Day 2
Day 2 — Main Conference
March 11, 2027
Continental Breakfast & Networking
Co-Chairs’ Opening Remarks
Growing demand for GLP-1 medicines and other obesity treatments is raising complex questions about eligibility, treatment duration, clinical outcomes and long-term funding. Public and private payers must determine which patients should qualify for coverage, how continued treatment should be assessed and how expanded use may affect drug budgets.
This session will examine the evidence and policy considerations shaping coverage decisions as indications, treatment options and demand evolve.
- Evaluating long-term clinical outcomes and the durability of treatment benefits
- Defining eligibility criteria, treatment duration and reassessment requirements for public and private coverage
- Forecasting budget impacts and determining how emerging indications, competing therapies and new evidence should inform reimbursement decisions
Morning Break & Networking
Precision medicines for small patient populations challenge conventional assessment and reimbursement approaches, particularly when early evidence is promising but uncertainty remains.
In this facilitated, case-based lab, participants will work in small groups to develop a fit-for-purpose assessment and funding approach for a hypothetical targeted therapy. Working through the case, they will determine evidence requirements, patient eligibility criteria, funding conditions and approaches to ongoing data collection and reassessment.
Groups will present their proposed approaches, followed by discussion to examine their practical implications for timely, equitable and sustainable access.
The arrival of HEMGENIX in Canadian clinical practice provides a timely case study in funding high-cost, one-time therapies. Following a pan-Canadian Pharmaceutical Alliance agreement, the treatment became publicly reimbursed in Ontario and British Columbia, and the first Canadian patient received it in May 2026. Yet questions remain about the durability of clinical benefit, the timing of potential cost offsets and how public payers can manage financial risk when long-term outcomes are still uncertain.
Our panelists will explore all this and more in our interactive case study.
- Evaluating the suitability of alternative payment models for one-time, high-cost gene therapies
- Identifying ways to link reimbursement arrangements to long-term clinical outcomes and treatment durability
- Developing approaches to measure realized cost offsets and strengthen payer accountability over time
Networking Lunch
Accelerated regulatory and reimbursement pathways aim to shorten the time between drug approval and public funding, yet delays persist after regulatory review. A 2026 study of Ontario listing timelines found that medicines funded through the FAST pilot reached public listing in a mean of 229 days, compared with 604 days for Project Orbis therapies and 625 days for Priority Review therapies outside Project Orbis.
These findings highlight opportunities to accelerate access beyond regulatory review alone. Meanwhile, the pan-Canadian Pharmaceutical Alliance (pCPA) is exploring options to expand its Early Negotiation Process (ENP) to include Priority Review and certain NOC/c therapies.
This session will examine lessons from existing pathways and opportunities to improve the transition from approval to public reimbursement.
- Determine which performance measures best assess whether accelerated pathways deliver meaningful improvements in patient access
- Identify implementation lessons that could inform more consistent approaches across provincial and territorial drug plans
- Evaluate how earlier payer engagement could help manufacturers prepare evidence, anticipate reimbursement requirements and plan market entry
Reimbursement decisions are only one part of the journey to treatment. Patients may still encounter high out-of-pocket costs, restrictive coverage criteria, administrative barriers and delays that affect their ability to access and continue prescribed medicines.
In this patient-led panel, advocates will share their perspectives on navigating Canada’s public and private drug coverage systems,
- Examining how reimbursement gaps, coverage requirements and financial barriers affect patients’ access to medicines
- Exploring how patient perspectives can better inform market access policy and reimbursement decisions
- Highlighting practical ways manufacturers, payers and policymakers can improve timely access to medicines
Afternoon Refreshment & Networking
This session will examine how manufacturers can assess the appropriate use of AI in reimbursement and ensure their methods and findings meet payer expectations.
- Examining practical applications of AI in evidence synthesis, health-economic modelling and real-world data analysis
- Assessing the reliability of AI-assisted analyses through validation, reproducibility and evaluation of potential bias
- Determining how manufacturers can ensure transparency, documentation and appropriate disclosure when preparing AI-assisted reimbursement submissions